Mubadala investment company injects US$250M worth of funds into Certara

WORLD – Mubadala Investment Company (Mubadala) has made an approximately US$250 million investment in Certara as a strategy move that will enable innovation to address unmet clinical needs and drive cost efficiencies.

Mubadala and certain existing institutional shareholders of Certara, including a shareholder affiliated with EQT, a private equity company, have entered into an agreement under which an affiliate of Mubadala will purchase an aggregate of 9,615,384 shares at $26 per share from the shareholders in a private transaction.

The transaction is scheduled to close on August 2, 2021. EQT will remain a significant shareholder in the company after the transaction, Mubadala said in a statement Wednesday.

“We are pleased to welcome a significant new investment from Mubadala, a sovereign investor with deep expertise in life sciences that is focused on creating lasting value,” said William F. Feehery, Chief Executive Officer of Certara.  “As a newly listed public company, we are excited by Mubadala’s recognition of Certara’s performance and position as a global leader in biosimulation, especially as we execute on our next phase of growth.”

The biosimulation market is poised to grow by US$2.09b during 2021-2025, progressing at a CAGR of 13.17% during the forecast period, according to Technavio Research Reports.

Certara accelerates medicines using biosimulation software and technology to transform traditional drug discovery and development. Its clients include more than 1,650 global biopharmaceutical companies.

Biosimulation is integral to drug development today, with fierce competition for expert scientists to run the simulations and interpret the results.

Certara recently announced its plans to venture into Africa as the next frontier for biosimulation by ensuring talents are trained.

“We see Africa as a sandbox of innovation, which is very different from the way many perceive the continent,” Rayner told BioSpace. “Where many see challenges and market failures, we see opportunities. Those challenges force us to be innovative in the way medicine is developed. Our view is that it’s very much a glass half full perspective.”

Certara supports several projects in Africa and knows first-hand the criticality of getting the clinical trial design right, so trials can be successfully executed.

The situation on the ground makes it extremely difficult for companies to conduct clinical trials there but makes it an ideal environment for biosimulation.

Certara is hopeful to have its biosimulation system far and wide across Africa and around the globe and through this training program and the huge boost it acquired in funding.

Would you like to get regular updates of such news articles? Subscribe to our HealthCare Africa News, email newsletters, which provide the latest news insights from Africa and the World’s health, pharma and biotech industry. SUBSCRIBE HERE

Related posts

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.